Indications › Obesity & overweight › orforglipron

orforglipron in obesity & overweight

orforglipron is approved in the US for obesity & overweight, and has 15 trials on file here in this condition. 14 of them are phase 3 or later. The next scheduled result is 2027-02.

15 registered trials study orforglipron (Foundayo) in obesity & overweight, 10 of them still active and 9 in phase 3. The next is due to report 2027-02.

Trials on file: 15
Active: 10
Active phase 3: 9
Participants in active trials: 8,942
Sponsors: 2
Scheduled readouts: 7

Scheduled to report

Dates are filed by the sponsor and move often. Each links to its own record and change history.

Est. completion	Trial	Phase	Participants
2027-02	A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) NCT06672549 · Eli Lilly and Company	P3	125
2027-08	A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes NCT06993792 · Eli Lilly and Company	P3	1,400
2027-08	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes NCT06972472 · Eli Lilly and Company	P3	600
2027-08	A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity NCT06972459 · Eli Lilly and Company	P3	800
2027-09	A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 NCT06948435 · Eli Lilly and Company	P3	487
2027-12	A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities NCT06672939 · Eli Lilly and Company	P3	150
2028-03	A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems NCT07790861 · Eli Lilly and Company	P3	192

All trials on file

Every registered trial of orforglipron grouped under obesity & overweight, largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities NCT05869903	Active, not recruiting	P3	Eli Lilly and Company
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk NCT05803421	Completed	P3	Eli Lilly and Company
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity NCT07794579	Recruiting	P3	Eli Lilly and Company
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes NCT05872620	Completed	P3	Eli Lilly and Company
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes NCT06993792	Active, not recruiting	P3	Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity NCT06972459	Active, not recruiting	P3	Eli Lilly and Company
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight NCT06649045	Completed	P3	Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes NCT06972472	Active, not recruiting	P3	Eli Lilly and Company
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 NCT06948435	Active, not recruiting	P3	Eli Lilly and Company
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities NCT05051579	Completed	P2	Eli Lilly and Company
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease NCT05931380	Completed	P3	Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems NCT07790861	Not yet recruiting	P3	Eli Lilly and Company
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities NCT06672939	Recruiting	P3	Eli Lilly and Company
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) NCT06672549	Recruiting	P3	Eli Lilly and Company
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation NCT07729332	Not yet recruiting	P4	Massachusetts General Hospital

See the full record for orforglipron, or every molecule being studied in obesity & overweight. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.